Therapeutic vaccines function by triggering a body immune response against a disease. The global therapeutic vaccines market was valued at USD 292 million in 2011. The introduction of therapeutic vaccines has opened up new avenues in the field of chronic disease treatment and prophylactic immunization. Provenge was the first U.S. FDA approved immunotherapy drug to treat prostate cancer in men in 2010, which has encouraged rigorous research and development initiatives by pharmaceutical companies to develop novel vaccines for untapped disease segments.
As a result of these initiatives, many more therapeutic vaccines are currently in the pipeline such as breast cancer vaccine, lung cancer vaccine; Alzheimer’s vaccine, malaria vaccine, and diabetes vaccine are expected to be introduced in the market during the period from 2012 to 2018.
The market is currently facing growth hindrances as R&D approaches, and regulatory and reimbursement policies are inconspicuous owing to the nascent nature of the market. However, regulatory bodies are working enthusiastically to lay out policies and growth strategies, due to the fact that it holds the potential to solve or curb chronic diseases, with no currently available treatments, such as HIV AIDS.
our components hold imperative importance in designing a therapeutic vaccine:
Antigens: These are substances that evoke an immune response from the body and are responsible for the production of antibodies
Adjuvants: These are immunological agents that help in modifying the effects of a drug or vaccine. Companies are now engaged in designing new adjuvants that will help in enhancing the immunogenicity of an antigen
Cost effective production systems for vaccines
Designing innovative drug delivery devices to enhance vaccine efficacy
The North American therapeutic vaccine market is expected to generate the maximum revenue in the global market during the forecasted period due to the presence of efficient R&D facilities and sophisticated medical infrastructures. The market is segmented into three major application segments namely oncology, infectious diseases and other chronic disorders.
The therapeutic vaccine market with oncology applications market held the majority of the market share in 2011, as most of the research and development exercises are expected to be directed towards this segment during 2012 to 2018.
Merck and GSK have strong therapeutic vaccine product pipelines and are expected to perform better during 2012 to 2018 than their competitors who have fewer products in the pipeline. Some of the other key players of the market include Sanofi-Pasteur, Cytos Biotechnology AG, and Intellect Neurosciences.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include :-
North America ,Asia Pacific ,Europe ,Rest of the World
Browse All Market Research Report : http://www.transparencymarketresearch.com/